-- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining ...
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for ...
Immix Biopharma, Inc. has announced that interim data from its Phase 1/2 NEXICART-2 trial of the CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis will be presented at the 2025 American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results